Symbio Muc Eye Drops

Dosing for Mucor Racemosus is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity level.

Immunotherapy (Subcutaneous Injection)

1. 1Build-up Phase: Treatment usually begins with a very dilute solution (e.g., 1:100,000 or 1:10,000 w/v). Injections are typically given 1 to 2 times per week. The dose is incrementally increased (e.g., 0.05 mL, 0.1 mL, 0.2 mL) until the 'Maintenance Dose' is reached.
2. 2Maintenance Phase: Once the highest tolerated dose is reached (often 0.5 mL of a 1:10 or 1:20 w/v solution), the interval between injections is increased to every 2 to 4 weeks. Maintenance therapy usually continues for 3 to 5 years to achieve long-term desensitization.

Diagnostic Testing

• Skin Prick Test: A single drop of a 1:10 or 1:20 w/v glycerinated extract is applied to the skin, followed by a puncture. Results are read after 15–20 minutes.
• Intradermal Test: If the prick test is negative, 0.02 mL of a much more dilute aqueous solution (e.g., 1:1,000 w/v) may be injected into the upper layer of the skin.

Mucor Racemosus is generally considered safe for use in children, typically those aged 5 years and older. Dosing schedules for children are similar to adult schedules but require even more cautious escalation. Because children may have difficulty communicating the early signs of a systemic reaction, they must be monitored closely by specialized pediatric allergy staff. There is limited data on the safety and efficacy of immunotherapy in children under the age of 5.

Renal Impairment

No specific dosage adjustments are provided by manufacturers for patients with kidney disease, as the proteins are metabolized proteolytically. However, the patient's overall health and ability to tolerate a potential systemic reaction must be considered.

Hepatic Impairment

No dosage adjustments are required for patients with liver disease, as the extract does not undergo hepatic CYP450 metabolism.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The use of epinephrine (the primary treatment for a severe reaction) may be more risky in this population, which may influence the decision to proceed with high-dose immunotherapy.

• Administration: This medication must ONLY be administered by a healthcare professional in a clinical setting equipped with emergency supplies (epinephrine, oxygen, IV fluids).
• Observation: Patients must remain in the clinic for at least 30 minutes after every injection to monitor for signs of anaphylaxis (a severe, life-threatening allergic reaction).
• Injection Site: Injections are given subcutaneously in the outer aspect of the upper arm. The site should not be massaged after the injection.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

If a dose is missed during the build-up phase, the next dose may need to be reduced to ensure safety.

• 1 week late: Continue with the scheduled dose.
• 2-3 weeks late: The dose may be held at the previous level or reduced.
• Over 4 weeks late: The build-up may need to be restarted from a much lower concentration.

Always consult your allergist if you miss an appointment.

An 'overdose' in the context of allergenic extracts usually refers to an injection of a concentration higher than what the patient's immune system can currently tolerate.

• Symptoms: Rapid onset of hives, swelling of the throat, wheezing, low blood pressure, or loss of consciousness.
• Emergency Measures: Immediate administration of epinephrine (adrenaline), followed by antihistamines, corticosteroids, and emergency transport to a hospital.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to self-administer these injections without medical guidance.

Most patients undergoing immunotherapy with Mucor Racemosus will experience local reactions. These are generally not dangerous but can be uncomfortable.

• Local Redness (Erythema): Redness at the injection site that usually appears within minutes and fades within hours.
• Local Swelling (Wheal): A raised, itchy bump at the injection site. If the swelling is smaller than the size of a half-dollar, it is considered a normal response.
• Itching (Pruritus): Localized itching that can be managed with over-the-counter antihistamines or cold compresses.

• Large Local Reactions: Swelling that extends beyond the immediate injection site, sometimes involving the entire upper arm. This may require a dose adjustment for the next visit.
• Fatigue: Some patients report feeling unusually tired for a few hours after their allergy shots.
• Mild Nasal Congestion: A temporary increase in hay fever symptoms shortly after administration.

• Generalized Hives (Urticaria): Itchy bumps appearing on parts of the body far from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Persistent Cough: A sign of mild bronchial irritation.

> Warning: Stop taking Mucor Racemosus and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis:

• Difficulty Breathing or Wheezing: Indicates constriction of the airways.
• Throat Tightness: Feeling as though the throat is closing or difficulty swallowing.
• Rapid or Weak Pulse: A sign of cardiovascular distress or dropping blood pressure.
• Dizziness or Fainting: Resulting from a sudden drop in blood pressure (hypotension).
• Nausea, Vomiting, or Diarrhea: Systemic allergic reactions can affect the gastrointestinal tract.
• Cyanosis: Bluish tint to the lips or fingernails, indicating lack of oxygen.

There are no known long-term 'toxic' effects of Mucor Racemosus extracts, as they are biological proteins. However, the primary long-term risk is the development of new sensitivities or the rare occurrence of 'serum sickness' (an immune complex disease), though this is extremely rare with modern, purified extracts. Most patients find that the long-term benefit of reduced allergy symptoms far outweighs the risks of the treatment.

While Mucor Racemosus may not have a specific 'Black Box' for the brand name, the FDA requires a general boxed warning for all allergenic extracts regarding the risk of severe anaphylaxis.

Summary of Warning:

• Allergenic extracts can cause severe, life-threatening systemic reactions, including anaphylaxis.
• They should only be administered by physicians who are exceptionally experienced in the treatment of allergic diseases.
• Patients must be observed for at least 30 minutes in an office equipped with emergency equipment.
• Patients with unstable asthma are at a higher risk for fatal reactions.

Report any unusual symptoms to your healthcare provider, even if they occur several hours after your injection.

Mucor Racemosus extract is a potent biological product. It is intended for use only by clinicians trained in allergy and immunology. Because the extract contains fungal proteins, it can trigger the very allergic symptoms it is meant to treat if not administered correctly. Patients must be in a stable state of health (e.g., no active asthma flare-ups or infections) before receiving an injection.

No FDA black box warnings for Mucor Racemosus specifically, but it falls under the mandatory class-wide warning for all allergenic extracts. This warning emphasizes that these products can cause anaphylaxis and must be administered in a setting where emergency resuscitation is possible. Fatalities have occurred when injections were given to patients with severe, uncontrolled asthma.

• Anaphylaxis Risk: This is the most significant risk. Reactions can occur within seconds or minutes. Patients should be prescribed an epinephrine auto-injector (e.g., EpiPen) and trained on how to use it in case of a delayed reaction after leaving the clinic.
• Asthma Status: Patients with severe or poorly controlled asthma (FEV1 < 70% of predicted) are at a significantly higher risk of a fatal reaction to immunotherapy. Injections should be withheld if the patient is experiencing increased wheezing or shortness of breath.
• Cardiovascular Disease: Patients with pre-existing heart conditions may be less able to survive the physiological stress of anaphylaxis or the side effects of epinephrine.
• Infection: If a patient has a fever or a significant respiratory infection, the dose should be postponed until they have recovered.

• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before each injection to ensure lung function is stable.
• Symptom Review: Before each dose, the clinician will ask about the reaction to the previous dose and any current allergy symptoms.
• 30-Minute Wait: This is a mandatory monitoring period following every administration.

Generally, Mucor Racemosus does not cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have been fully cleared by a medical professional.

There is no direct chemical interaction between alcohol and Mucor Racemosus. However, alcohol can cause vasodilation (widening of blood vessels), which may theoretically increase the speed of allergen absorption or worsen the symptoms of an allergic reaction. It is best to avoid alcohol for several hours before and after an injection.

If immunotherapy is discontinued, there is no 'withdrawal syndrome.' However, the patient's allergy symptoms will likely return to their baseline levels over time. If a patient experiences a severe systemic reaction, the healthcare provider may decide to permanently discontinue the treatment.

> Important: Discuss all your medical conditions, especially respiratory or heart issues, with your healthcare provider before starting Mucor Racemosus.

• Beta-Blockers (e.g., Propranolol, Atenolol, Metoprolol): These medications are used for high blood pressure and heart conditions. They are contraindicated (should not be used) in patients receiving allergenic extracts because they block the effects of epinephrine. If a patient on a beta-blocker has anaphylaxis, the emergency treatment (epinephrine) may not work, leading to a potentially fatal outcome.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): These may increase the risk of systemic reactions or worsen the severity of anaphylaxis by interfering with the body's natural ability to break down inflammatory mediators.
• MAO Inhibitors (e.g., Phenelzine): These can interfere with the metabolism of epinephrine, potentially causing a dangerous spike in blood pressure if emergency treatment is required.
• Other Immunotherapy: Receiving multiple types of allergy shots (e.g., for molds and for pollens) increases the total 'allergen load' on the immune system, requiring careful coordination of dosing.

• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can potentiate the effects of epinephrine, making the management of a reaction more complex.
• Systemic Steroids: While often used to treat allergies, long-term use of high-dose steroids can suppress the immune response, potentially making immunotherapy less effective.

There are no known direct food interactions with Mucor Racemosus extract. However, patients with 'Oral Allergy Syndrome' or known food allergies should be cautious, as a systemic reaction to a food could be mistaken for a reaction to the extract, or vice versa.

There is limited data on herbal interactions. However, supplements that have 'immune-boosting' claims (like Echinacea or Elderberry) should be discussed with an allergist, as they could theoretically interfere with the immune-modulating goals of immunotherapy.

• Skin Tests: Mucor Racemosus will obviously interfere with future skin tests for the same allergen.
• In Vitro IgE Testing (ImmunoCap): Immunotherapy will eventually lead to a decrease in specific IgE levels and an increase in IgG4 levels, which is the intended clinical result but should be noted when interpreting lab reports.

For each major interaction, the mechanism involves either the interference with the body's response to emergency medication (pharmacodynamic) or the modulation of the immune system's sensitivity threshold. The management strategy always involves a thorough medication review by the allergist before the first dose is administered.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure or heart health.

Mucor Racemosus must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients with a low FEV1 (Forced Expiratory Volume) are at an unacceptably high risk of death from a systemic reaction. The airway is already compromised and cannot tolerate further constriction.
2. 2Recent Myocardial Infarction (Heart Attack): The cardiovascular system must be stable to handle the potential stress of an allergic reaction or the administration of epinephrine.
3. 3Beta-Blocker Therapy: As mentioned, the inability to respond to epinephrine makes immunotherapy too dangerous to perform.
4. 4History of Severe Reaction to This Specific Extract: If a patient has previously had a life-threatening response to Mucor racemosus extract, the risks of continuing therapy usually outweigh the benefits.

These conditions require a careful risk-benefit analysis by the physician:

• Pregnancy: While not strictly contraindicated to continue maintenance therapy, it is generally recommended NOT to start a new immunotherapy program during pregnancy due to the risk of anaphylaxis-induced fetal distress.
• Autoimmune Diseases: In patients with conditions like Lupus or Rheumatoid Arthritis, stimulating the immune system with extracts could theoretically worsen the underlying disease.
• Malignancy: Patients with active cancer may have altered immune responses.
• Young Children (<5 years): The difficulty in monitoring and communicating symptoms makes this a relative contraindication.

Patients allergic to Mucor racemosus may show cross-reactivity with other members of the Mucorales order (such as Rhizopus). This means they may react to skin tests for these related molds even if they haven't had direct exposure. This is due to the similarity in the protein structures across different fungal species.

> Important: Your healthcare provider will evaluate your complete medical history, including your current medications and lung function, before prescribing Mucor Racemosus.

Pregnancy Category: C (by historical standards).

There are no adequate and well-controlled studies of Mucor Racemosus in pregnant women. The primary concern is not the extract itself, but the risk of anaphylaxis. A severe allergic reaction in the mother can cause systemic hypotension (low blood pressure), leading to uterine hypoperfusion and fetal hypoxia (lack of oxygen to the baby).

• Starting Therapy: Clinicians generally advise against starting the build-up phase during pregnancy.
• Maintenance Therapy: If a woman is already on a stable maintenance dose and becomes pregnant, the treatment is often continued, as the risk of a reaction is much lower at this stage.

It is not known whether the fungal proteins from the extract are excreted in human milk. However, because they are natural proteins and are administered in very small quantities, the risk to a nursing infant is considered negligible. The benefits of the mother's allergy control should be weighed against any theoretical risks.

Allergen immunotherapy is widely used in the pediatric population. It is particularly valued because it may prevent the 'allergic march'—the progression from allergic rhinitis to asthma.

• Age Limit: Most allergists wait until a child is at least 5 years old so they can accurately describe their symptoms.
• Growth: There is no evidence that allergenic extracts affect growth or development.

Patients over age 65 may receive Mucor Racemosus, but they require extra screening. The presence of underlying heart disease or the use of multiple medications (polypharmacy) increases the risk profile. Renal clearance of protein metabolites may be slower, but this rarely requires a dose adjustment.

There is no evidence that renal impairment significantly alters the safety of Mucor Racemosus. Because the proteins are broken down by proteases throughout the body, the kidneys are not the sole route of elimination. However, patients with end-stage renal disease should be monitored for overall fluid balance if they require emergency treatment for a reaction.

Liver disease does not interfere with the processing of allergenic extracts. No dose adjustments are required for patients with various stages of hepatic impairment, provided they are otherwise stable.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or develop new health problems during treatment.

Mucor Racemosus extract acts as an immunomodulator. In the diagnostic phase, it acts as an antigen that cross-links IgE on mast cells. In the therapeutic phase, it induces a shift from a Th2-dominated immune response (which produces IgE and promotes allergy) to a Th1/Treg-dominated response. This involves the production of Interleukin-10, which suppresses the inflammatory activity of mast cells, basophils, and eosinophils.

• Dose-Response: There is a clear dose-response relationship in immunotherapy; higher doses (within the maintenance range) are generally more effective than low doses but carry a higher risk of side effects.
• Onset: The diagnostic response (skin test) occurs within 15–20 minutes. The therapeutic effect (symptom reduction) typically takes 3 to 6 months of build-up therapy to become noticeable.
• Duration: The effects of a successful 3-to-5-year course of immunotherapy can last for many years, even after the injections are stopped.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous Injection) |

| Protein Binding | Minimal (interacts with antibodies) |

| Half-life | Varies (Proteins degraded within hours/days) |

| Tmax | 15–30 minutes (for local reaction) |

| Metabolism | Proteolytic degradation |

| Excretion | Renal (as amino acids/peptides) |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides derived from Mucor racemosus.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for various fungal allergens.
• Solubility: Soluble in aqueous solutions and 50% glycerin.
• Structure: Includes major allergens such as proteases and heat-shock proteins common to the Mucorales order.

Mucor Racemosus belongs to the Non-Standardized Fungal Allergenic Extract class. It is grouped with other mold extracts like Alternaria, Cladosporium, and Aspergillus. Unlike standardized extracts (like Cat Hair or Ragweed), the potency of Mucor is determined by the manufacturer's internal standards rather than a universal FDA reference standard.